Charles River Laboratories stock gains as valuation stretches above fair value estimates

Published on 09/03/2026 at 09:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Laboratories stock is trading close to the upper end of its recent range as of early September 2026, while valuation metrics point to a premium versus several fair value estimates and sector peers.

CRL, US1598641074, Illustration mit AI erstellt.

Charles River Laboratories International stock (ISIN US1598641074) is trading at USD 291.76 as of September 2, 2026, after a 3.3% move that pushed the shares toward the upper end of their 52-week range between USD 144.26 and USD 302.40, according to data compiled by GuruFocus.

Valuation premium versus fair value models

The recent price level puts Charles River Laboratories significantly above several intrinsic value estimates. According to an analysis on Simply Wall St, the company’s fair value is estimated at USD 230.93 per share, implying around 21 percent downside from the current market level as of early September 2026. This gap between market price and model-based valuation underlines that investors are paying a substantial premium for the stock’s growth profile and contract research exposure.

Peer comparisons also illustrate this premium. Data compiled by Macrotrends show Charles River Laboratories with a market capitalization of approximately USD 8.071 billion and a price-to-earnings ratio of 15.31 as part of a group of contract research and life science service companies. In the same overview, Solventum is listed with a latest closing price of USD 91.90 on September 2, 2026 and a market capitalization of USD 13.5 billion, making Charles River Laboratories smaller by market value but trading at a valuation that investors appear willing to stretch, given its specialized preclinical research niche.

Stock performance and investor reaction

The 3.3 percent share price increase to USD 291.76 on September 2, 2026 reflects renewed investor interest in Charles River Laboratories ahead of upcoming corporate events, even though the stock is already close to its 52-week high of USD 302.40, based on the GuruFocus pricing snapshot. The move has taken place within a broader context in which other life science and tools names such as Bio-Techne have delivered solid one-year returns, with Bio-Techne’s stock up 23.47 percent versus 11.99 percent for the S&P 500 over the 12 months to September 2, 2026, according to data shown by Yahoo Finance.

Against that backdrop, Charles River Laboratories’ valuation relative to the USD 230.93 fair value estimate signals that investors are willing to price in continued earnings growth, margin resilience and steady demand for outsourced preclinical and early-stage research services. For retail investors, the quantified comparison between the current price and the fair value estimate is a central data point: at the present level around USD 291.76, the stock sits more than USD 60 above that model-based valuation, a spread that may become a reference for future re-rating or consolidation phases.

Go deeper

More data and context on Charles River Laboratories

Background articles and historical figures offer additional insight into how the Charles River Laboratories stock valuation has evolved over time and how it compares with peers in the contract research sector.

More articles on this ISIN Investor Relations

Preclinical services as a revenue driver

Charles River Laboratories International, Inc. generates most of its revenue by providing outsourced research and development services to pharmaceutical and biotechnology companies as well as academic and government institutions. The company’s portfolio spans discovery, safety assessment, and manufacturing support, with a focus on animal models, lab services, and related analytical capabilities. These offerings make Charles River Laboratories a key partner in reducing time-to-market and costs for clients seeking to advance new therapeutics through early-stage pipelines.

Within the broader tools and contract research space, demand for such services has historically been relatively stable, driven by continuous R&D spending and the need to manage complexity in preclinical and early clinical development. While detailed current-quarter revenue and earnings figures for Charles River Laboratories are not explicitly provided in the available same-day sources for this call, historical annual reports and prior quarter disclosures indicate that the company has steadily expanded its service mix, including acquisitions and strategic partnerships that aim to broaden its capabilities. Investors often track segment revenue shares and margin trends in discovery and safety assessment as indicators of how efficiently the company converts its scientific platform into profitable growth.

Price level and investor perspective

As of the latest available close on September 2, 2026, Charles River Laboratories stock is quoted at USD 291.76 on the New York Stock Exchange, within a defined 52-week trading corridor from USD 144.26 at the low end to USD 302.40 at the high. At this level, the company’s market capitalization stands near USD 8.071 billion in the Macrotrends peer table, underscoring its position as a mid-cap player in the global contract research and life sciences tools space.

For investors, the key takeaway from this valuation snapshot is that Charles River Laboratories stock currently trades closer to the top of its recent price band and materially above at least one fair value estimate. Future earnings releases and any adjustments to guidance or analyst consensus will likely determine whether the premium narrows through price consolidation or is validated by stronger-than-expected growth.